Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 16/20 | 0.66 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | TEK | Q02763 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12045607 | 0.93 | DGAT1 (0.60) | DGAT1SOAT2KDRUSP30LCK | |
| SCHEMBL9985031 | 0.88 | DGAT1 (0.69) | DGAT1SOAT2USP30 | |
| SCHEMBL9984145 | 0.86 | DGAT1 (0.67) | DGAT1SOAT2 | |
| SCHEMBL9984799 | 0.85 | DGAT1 (0.52) | DGAT1SOAT2 | |
| SCHEMBL9985010 | 0.84 | DGAT1 (0.68) | DGAT1SOAT2 | |
| SCHEMBL9985300 | 0.82 | DGAT1 (0.76) | DGAT1SOAT2KDRUSP30LCK | |
| SCHEMBL9985305 | 0.82 | DGAT1 (0.76) | DGAT1SOAT2KDRUSP30LCK | |
| SCHEMBL9984246 | 0.82 | DGAT1 (0.70) | DGAT1SOAT2 | |
| SCHEMBL12045615 | 0.81 | DGAT1 (0.63) | DGAT1SOAT2USP30 | |
| SCHEMBL12045608 | 0.81 | DGAT1 (0.62) | DGAT1SOAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637507-B2 | Bicyclic compounds as inhibitors of diacylglycerol acyltransferase | MERCK SHARP & DOHME CORP. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637507-B2 | Bicyclic compounds as inhibitors of diacylglycerol acyltransferase | MERCK SHARP & DOHME CORP. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637507-B2 | Bicyclic compounds as inhibitors of diacylglycerol acyltransferase | MERCK SHARP & DOHME CORP. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20110319403-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319403-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319403-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319403-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | DGAT2, DGAT1, LCAT | DGAT1 2/4885SOAT2 6/4885KDR 3483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.